



PRESS RELEASE

Information submitted for publication on 29 November 2012 at 8:45 (CET).

Results from Probi's Clinical Studies in Immune and Gut Health

The results from Probi's two clinical studies conducted in 2012, one in immune health and one in gut health, are now available. Preliminary analyses of the data show that the results from the studies did not meet expectations. Probi will consequently not apply to the European Food Safety Authority (EFSA) for health claims within the EU at this point.

"We have gained important new knowledge from the studies and the data will now be analysed in more detail to guide continued clinical development within immune and gut health, areas where we have previously demonstrated very good results", says Michael Oredsson, CEO at Probi.

This is the type of information that Probi AB is required to disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR MORE INFORMATION, PLEASE CONTACT:

Michael Oredsson, CEO, Probi, tel +46 46 286 89 23 or mobile +46 707 18 89 30

e-mail: michael.oredsson@probi.se

Per Lundin, Chairman of the Board, Probi, mobile +46 705 74 11 71, e-mail: per.lundin@transit.se

ABOUT PROBI

Probi is a leading player in probiotic research and the development of efficient and well-documented probiotics. Its research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi's customers are leading companies in the functional foods and consumer healthcare business areas. Total income for 2011 totalled MSEK 95.0. Probi's share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders. For more information, please visit www.probi.se.